|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
___________________
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2016
Commission File Number: 001-32001
___________________
Aptose Biosciences Inc. (Translation of registrant's name into English)
5955 Airport Road, Suite 228 Canada ___________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) ☐
|
DOCUMENTS FILED AS PART OF THIS FORM 6-K
See Exhibit Index hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Aptose Biosciences Inc. | |||
| Date: June 21, 2016 | By: | “Gregory Chow” | |
| Name: | Gregory Chow | ||
| Title: | Senior Vice President and Chief Financial Officer | ||
EXHIBIT LIST
| 99.1 | Report of Voting Results | |